^
    12ms
    A Study to Explore the Reasonable Dosage and Evaluate the Efficacy, Safety and Tolerability of HLX10 and HLX04 with or Without HLX53 in Untreated, Locally Advanced or Metastatic Hepatocellular Carcinoma Patients. (clinicaltrials.gov)
    P2, N=117, Recruiting, Shanghai Henlius Biotech | Not yet recruiting --> Recruiting
    Enrollment open • Metastases
    |
    Hetronifly (serplulimab) • HLX-53 • Hanbeitai (bevacizumab biosimilar)
    over1year
    A Study to Explore the Reasonable Dosage and Evaluate the Efficacy, Safety and Tolerability of HLX10 and HLX04 With or Without HLX53 in Untreated, Locally Advanced or Metastatic Hepatocellular Carcinoma Patients. (clinicaltrials.gov)
    P2, N=117, Not yet recruiting, Shanghai Henlius Biotech
    New P2 trial • Metastases
    |
    Hetronifly (serplulimab) • HLX-53 • Hanbeitai (bevacizumab biosimilar)
    over1year
    A Phase I Clinical Study of HLX53 in Advanced/Metastatic Solid Tumors (clinicaltrials.gov)
    P1, N=12, Active, not recruiting, Shanghai Henlius Biotech | Recruiting --> Active, not recruiting | N=20 --> 12 | Trial primary completion date: Aug 2024 --> Dec 2024
    Enrollment closed • Enrollment change • Trial primary completion date • Metastases
    |
    HLX-53
    over2years
    A Phase I Clinical Study of HLX53 in Advanced/Metastatic Solid Tumors or Lymphoma (clinicaltrials.gov)
    P1, N=20, Recruiting, Shanghai Henlius Biotech | Not yet recruiting --> Recruiting
    Enrollment open • Metastases
    |
    TIGIT (T Cell Immunoreceptor With Ig And ITIM Domains 2)
    |
    HLX-53
    over3years
    A Phase I Clinical Study of HLX53 in Advanced/Metastatic Solid Tumors or Lymphoma (clinicaltrials.gov)
    P1, N=20, Not yet recruiting, Shanghai Henlius Biotech
    New P1 trial
    |
    TIGIT (T Cell Immunoreceptor With Ig And ITIM Domains 2)
    |
    HLX-53